In case you missed it, Alto was recently showcased on a prominent Silicon Valley billboard! It’s great to see our precision approach highlighted in different ways as we move closer to delivering #PrecisionMedicine for the brain. Learn more: brnw.ch/21wIILM $ANRO

We recently initiated a Phase 2 study of ALTO-203 in people with MDD & higher levels of #anhedonia . We look forward to continuing to study the potential of #PrecisionPsychiatry . Check out this Psychiatric Times article to learn more: brnw.ch/21wIEKC

On #WorldHealthDay , we recognize the barriers people face in trying to obtain healthcare & treatments. We’re committed to increasing access to effective, precise #MentalHealth & working to develop novel treatments for those in need. Learn more: brnw.ch/21wIAu8

One-size-fits-all treatments for conditions like #depression and #schizophrenia continue to fall short. Our CEO, Amit Etkin, discusses the need for #PrecisionPsychiatry and Alto’s work in this @Axios article. Read it here: brnw.ch/21wIykz

Today we announced the initiation of our Phase 2 study of ALTO-203 in patients with #MajorDepressiveDisorder & elevated #anhedonia . We look forward to further evaluating the pharmacodynamics, pharmacokinetics, and tolerability of ALTO-203. Read more: brnw.ch/21wIt52

Since our founding in 2019, we’ve:
☑️Grown our team to 60+ full-time employees
☑️Achieved 3 positive phase 2a readouts
☑️Validated our Precision Psychiatry Platform™
☑️Expanded to new indications
☑️Announced the closing of our IPO on NYSE
More here: brnw.ch/21wIj7S

Our goal is to redefine psychiatry by leveraging neurobiology to develop personalized treatment options. Hear more from CEO Amit Etkin about the need for improved mental health treatments & our work to make #PrecisionPsychiatry a reality for patients: brnw.ch/21wIeBm

2023 was a year of growth for Alto, as we realized positive data from Phase 2 studies leveraging our Precision Psychiatry Platform™ and kicked off 2024 with an oversubscribed IPO. Read more in our Full Year 2023 Earnings press release: brnw.ch/21wI6pL $ANRO

Today at 11:30 a.m. ET, our CEO Amit Etkin will present on our work to develop #PrecisionMedicine for the brain at the Stifel 2024 Virtual CNS Days. Register for the presentation and tune in here: brnw.ch/21wI2Rs

During UBS' Virtual CNS Day, our CEO Amit Etkin will present on our #PrecisionPsychiatry platform and its potential to help patients in need. Tune into the presentation here: brnw.ch/21wHYtB

This year's ECNP New Frontiers Meeting will feature our CEO Amit Etkin discussing the rationale & impact of a new diagnostic framework based on a biological approach to understanding #neuropsychiatric diseases. Learn more about his presentation: brnw.ch/21wHX22 #ECNP2024

We had a great time celebrating the $ANRO listing on NYSE 🏛 last month. We're excited to continue our work developing #PrecisionMedicine for the brain. Check out our billboard featured in Times Square!

🧠 #BrainAwarenessWeek 2024 is here! Brain science has an immense impact on advancing meaningful #neuropsychiatric treatments, and it's important to broaden our understanding of the brain to improve #mentalhealth . Learn more from Dana Foundation🧠 here: brnw.ch/21wHM0f

Help us welcome Maha Radhakrishnan, M.D., to Alto's Board of Directors! An accomplished industry executive with decades of experience, Dr. Radhakrishnan will be extremely valuable in making #PrecisionPsychiatry a reality for patients. More here: brnw.ch/21wHLvR

The road to eliminating trial-and-error begins with science. In this STAT First Opinion piece, our CEO Amit Etkin calls for a shift in how we think about diagnosing & treating #MentalHealth conditions. Read it here (subscribers only): statnews.com/2024/03/08/psy…

Don't miss Alto at these upcoming investor conferences:

🔬 Jefferies Biotech on the Bay Summit in Miami 3/12-3/13
💻 UBS Virtual CNS Day 3/18
🧠 Stifel 2024 Virtual CNS Days 3/20

Reach out if you'd like to connect! More details here: brnw.ch/21wHF2J

Meet Mark Taylor, Alto's Senior Clinical Data Manager, who brings over 30 years of experience to our team. When he isn't busy with clinical data management and database development, he's likely writing. In 2024, he plans to self-publish an epic fantasy novel! 📚 #MeetTheTeam

We've already achieved major milestones in the new year & are pleased to be recognized by PharmaVoice as a #biotech company to watch in 2024! Read about our recent IPO, positive Phase 2 data & near-term readouts from our #PrecisionPsychiatry studies: brnw.ch/21wHrr0

Are you attending TD Cowen's Annual Healthcare Conference? Catch our CEO Amit Etkin’s presentation on March 5. Learn more here: brnw.ch/21wHmE4

Our team: data scientists 🤝 clinical experts. We put data at the forefront of our work to inform our #PrecisionPsychiatry approach. Learn how we are working to eliminate trial-and-error from #MentalHealth drug development: brnw.ch/21wHbsn